ZINCPharmer-Based Identification of Multi-Target Inhibitors for Erectile Dysfunction: Pharmacophore Virtual Screening and Molecular Docking of Commercially Available Compounds
Abstract
Abstract Erectile dysfunction (ED) affects approximately 300 million men globally, with current phosphodiesterase-5 (PDE-5) inhibitors associated with cardiovascular complications, headache, and addiction potential. This study employed ZINCPharmer pharmacophore-based virtual screening to identify novel multi-target inhibitors from commercially available compounds addressing multiple ED pathophysiological pathways. Using established PDE-5 inhibitors as query templates, four hit compounds were evaluated through molecular docking against PDE-5, arginase, protein kinase C (PKC), and O-GlcNAc transferase (OGT). Compound 4 demonstrated superior multi-target binding performance with strongest PDE-5 affinity (-9.11 kcal/mol versus − 8.96 kcal/mol for sildenafil), exceptional O-GlcNAc transferase binding energy (-45.41 kcal/mol, surpassing sildenafil at -31.00 kcal/mol), and favorable PKC binding (-52.13 kcal/mol), indicating robust polypharmacological potential. Notably, its higher LD 50 value (1000 mg/kg) suggests wider therapeutic window compared to Compound 1 (380 mg/kg), despite two Lipinski violations and low gastrointestinal absorption requiring optimization. Compound 1 exhibited remarkably favorable arginase binding energy (-3.63 kcal/mol), zero Lipinski violations, high gastrointestinal absorption, non-blood-brain barrier permeability, and minimal CYP 450 inhibition. Toxicological predictions indicated hepatotoxicity for Compound 4 and nephrotoxicity for Compound 1, though…
How strong is the evidence?
Evidence Hub reads this as a preprint, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 300 participants or records.
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.